Prognostic Factors for Visual Outcomes Following the First Episode of NMOSD-Related Optic Neuritis in Affected Eyes. 2020

Watcharaporn Thongmee, and Tanyatuth Padungkiatsagul, and Panitha Jindahra, and Chaiyos Khongkhatithum, and Lunliya Thampratankul, and Kavin Vanikieti
Department of Ophthalmology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

OBJECTIVE We aim to identify prognostic factors for visual outcomes following a first episode of neuromyelitis optica spectrum disorder-related optic neuritis (NMOSD-ON) in affected eyes. METHODS This was a single-center, retrospective study. The study included 50 individuals who were diagnosed with NMOSD-ON (63 affected eyes) in a tertiary institution over a 12-year period. Data regarding any second, or higher, episodes of NMOSD-ON in each eye were not taken into consideration. Medical records of included individuals were reviewed. Demographic data, clinical and magnetic resonance imaging characteristics, and treatment outcomes were collected. Main outcome measures of the study were prognostic factors for good visual outcome (best-corrected visual acuity (BCVA) ≥ 20/200) following an initial episode of NMOSD-ON in affected eyes. RESULTS Sixty-three affected eyes of 50 individuals (3 men and 47 women) were included. BCVA at nadir that was better than counting fingers (CF) (odds ratio 10.43, 95% confidence interval 1.04, 104.45, p = 0.046) and time from NMOSD-ON onset to intravenous methylprednisolone (IVMP), less than 21 days (odds ratio 10.73, 95% confidence interval 1.91, 60.01, p = 0.007), were significantly associated with good visual outcomes. CONCLUSIONS BCVA at nadir that was better than CF and treatment with IVMP within 21 days of symptom onset were important prognostic factors of good visual outcomes following a first episode of NMOSD-ON in affected eyes.

UI MeSH Term Description Entries

Related Publications

Watcharaporn Thongmee, and Tanyatuth Padungkiatsagul, and Panitha Jindahra, and Chaiyos Khongkhatithum, and Lunliya Thampratankul, and Kavin Vanikieti
January 2024, Clinical ophthalmology (Auckland, N.Z.),
Watcharaporn Thongmee, and Tanyatuth Padungkiatsagul, and Panitha Jindahra, and Chaiyos Khongkhatithum, and Lunliya Thampratankul, and Kavin Vanikieti
February 2023, Vision (Basel, Switzerland),
Watcharaporn Thongmee, and Tanyatuth Padungkiatsagul, and Panitha Jindahra, and Chaiyos Khongkhatithum, and Lunliya Thampratankul, and Kavin Vanikieti
September 2022, European journal of neurology,
Watcharaporn Thongmee, and Tanyatuth Padungkiatsagul, and Panitha Jindahra, and Chaiyos Khongkhatithum, and Lunliya Thampratankul, and Kavin Vanikieti
November 2025, Documenta ophthalmologica. Advances in ophthalmology,
Watcharaporn Thongmee, and Tanyatuth Padungkiatsagul, and Panitha Jindahra, and Chaiyos Khongkhatithum, and Lunliya Thampratankul, and Kavin Vanikieti
October 2022, Multiple sclerosis and related disorders,
Watcharaporn Thongmee, and Tanyatuth Padungkiatsagul, and Panitha Jindahra, and Chaiyos Khongkhatithum, and Lunliya Thampratankul, and Kavin Vanikieti
April 2023, Multiple sclerosis and related disorders,
Watcharaporn Thongmee, and Tanyatuth Padungkiatsagul, and Panitha Jindahra, and Chaiyos Khongkhatithum, and Lunliya Thampratankul, and Kavin Vanikieti
January 2015, American journal of ophthalmology,
Watcharaporn Thongmee, and Tanyatuth Padungkiatsagul, and Panitha Jindahra, and Chaiyos Khongkhatithum, and Lunliya Thampratankul, and Kavin Vanikieti
September 2014, American journal of ophthalmology,
Watcharaporn Thongmee, and Tanyatuth Padungkiatsagul, and Panitha Jindahra, and Chaiyos Khongkhatithum, and Lunliya Thampratankul, and Kavin Vanikieti
March 2020, Neurology(R) neuroimmunology & neuroinflammation,
Watcharaporn Thongmee, and Tanyatuth Padungkiatsagul, and Panitha Jindahra, and Chaiyos Khongkhatithum, and Lunliya Thampratankul, and Kavin Vanikieti
March 2001, Yan ke xue bao = Eye science,
Copied contents to your clipboard!